Erectile Dysfunction in Patients Treated with Selpercatinib for <i>RET</i> -Altered Thyroid Cancer
Antonio Matrone, Rossella Elisei(University of Pisa), Rhonda Siddall(Royal North Shore Hospital), Bruce Robinson(University of Michigan), Carla Gambale, Matti L. Gild(Memorial Sloan Kettering Cancer Center), Cyrus Sayehli(Universitätsklinikum Würzburg), Matthias Kroiß, Alessandro Prete, Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Sarah Hamidi(The University of Texas MD Anderson Cancer Center)
Cited by 6
Related Papers
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|392
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
|Cancer Discovery|2021|282
Denosumab for Treatment of Hypercalcemia of Malignancy
|The Journal of Clinical Endocrinology & Metabolism|2014|200